Release date:2020-03-05
AVANC PHARMACEUTICAL CO.,LTD
AVANC PHARMACEUTICAL CO.,LTD
About Avanc Pharma关于奥鸿药业
About Avanc Pharma
关于奥鸿药业
Avanc Pharmaceutical Co., Ltd (Avanc Pharma or the Company), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, focuses on innovative drug R&D, production and distribution and has a long-term commitment to the nervous system, oncology, perioperative drugs and pediatric drugs. The Company has been granted 48 patents cumulatively, with another 30-plus products in the pipeline. Annual sales totals RMB 4 billion approximately. With sufficient capital at its disposal, Avanc Pharma has built world-class state-of-the-art pharmaceutical bases, and developed business across the entire pharmaceutical supply chain. A strategy defined by “endogenous growth, exogenous expansion and integrated development” is being implemented in an effort to become a domestic leader with global competitiveness.
National High-Tech Company
China Top 100 Industrial Companies of the Chemical and Pharmaceutical Industry
China Top Growth Business Brands of the Chemical and Pharmaceutical Industry
China Drug Quality and Integrity Role Models of the Pharmaceutical Industry
Core Products
Core Products
Care For Life And Health
Care For Life And Health
CHANGTUONING ® (Penehyclidine Hydrochloride Injection), a brand-name drug of the Company, the world’s first-in-class selective anticholinergic drug and a class-I new drug in China, is mainly applied in pre-anesthetic medication and the treatment of organic phosphorus poisoning; BANGTING® (Hemocoagulase For Injection), another brand-name drug of the Company, is a well-recognized brand in the hemostatics field; AODEJIN® (Deproteinised Calf Blood Serum Injection), also a brand-name drug, is China’s first-in-class biological agent intended for the treatment of Nervous Functional Deficiency (NFD), among other diseases, and is a leading brand in the cerebrovascular and peripheral vascular agent segment.
R&D Fields
R&D Fields
Innovation-driven Business Development
Innovation-driven Business Development
News Center
News Center
Avanc Pharma, a national high-tech firm and a province- and city-level core pharmaceutical firm, has achieved high-standard, high-efficiency and high-quality leapfrog development and made significant contribution to local economic and social development, thanks to stable production and operation, capital adequacy, strong innovation capabilities and a complete product lineup.
锦州奥鸿药业有限责任公司AVANC PHARMACEUTICAL CO.,LTD
锦州奥鸿药业有限责任公司
AVANC PHARMACEUTICAL CO.,LTD
Address：55 Songshan Avenue, Taihe District, Jinzhou, Liaoning Province
Tel：+86 416 7900500
Fax：+86 416 2116616
Postal Code：121013
Business Information：+86 416-7900160（Marketing Management Center）
Drug Warning：+86 416-3885143（Safe Use of Drugs）
Join Us：+86 416-7900570（HR Management Center）
Media：+86 416-7900509（Brand Publicity）
Care For Life And Health
关爱生命 共享健康
To become a domestic leader with global competitiveness
Avanc Pharmaceutical Co., Ltd (Avanc Pharma or the Company), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, focuses on innovative drug R&D, production and distribution and has a long-term commitment to the nervous system, oncology, perioperative drugs and pediatric drugs. The Company has been granted 37 patents cumulatively, with another 30-plus products in the pipeline. Annual sales totals RMB 4 billion approximately. With sufficient capital at its disposal, Avanc Pharma has built world-class state-of-the-art pharmaceutical bases, and developed business across the entire pharmaceutical supply chain. A strategy defined by “endogenous growth, exogenous expansion and integrated development” is being implemented in an effort to become a domestic leader with global competitiveness.
R&D and Innovation
Avanc Pharma is committed to innovation-driven business development and is exploring deeper into the nervous system, oncology, perioperative drugs and pediatric drugs. In addition to 37 granted patents, the Company has 30-plus new drugs in the pipeline, including three new drugs of class 1.1, all supported by the “National New Drug Innovation Program”. While importing generic drugs with a high-tech barrier, the Company stays focused on pediatric drugs targeting common and uncommon diseases seen in children and new formulations ideal for pediatric medication, and makes continued efforts to expand its R&D pipelines and build a core competive edge of its products.
Nervous System
神经系统
Oncology
抗肿瘤
Perioperative Drugs
围手术期
Pediatric Drugs
儿童用药
Core Products
CHANGTUONING
®
（Penehyclidine Hydrochloride Injection）
CHANGTUONING ® (Penehyclidine Hydrochloride Injection), a core brand-name drug of the Company, the world’s first-in-class selective anticholinergic drug and a class-I new drug in China, is mainly applied in preanesthetic medication and the treatment of organic phosphorus poisoning and included in the National Reimbursement Drug List, National Essential Drug List, National First-Aid (Emergency Treatment) Drug List and the Catalog of China’s Marketed Drugs
BANGTING®
(Hemocoagulase For Injection)
BANGTING® (Hemocoagulase For Injection), another brand-name drug of the Company, is a well-recognized brand in the hemostatics field and ranks third by sales among products of the same kind.
AODEJIN®
(Deproteinised Calf Blood Serum Injection)
AODEJIN® (Deproteinised Calf Blood Serum Injection), also a brand-name drug, is China’s first-in-class biological agent intended for the treatment of Nervous Functional Deficiency (NFD), among other diseases, and is a leading brand in the cerebrovascular and peripheral vascular agent segment.
XINMAILIN®
(Glutamine Granules)
Glutamine Granules is mainly used to repair and rebuild damaged gastrointestinal mucosa, replenish glutamine after burns, traumas and major operations, and as an adjunctive therapy for cases of catabolism and hypermetabolism
News Center